Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
By Elias SchisgallShares of Kodiak Sciences surged ahead of the company's planned readout of topline results from a Phase 3 study of an eye disease treatment.The stock was up 17% to $38 in after-hours trading on Friday. Shares closed down 2.6% at $32.35, and are up 16% year-to-date.The biotechnolog…